ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $5.96 and traded as low as $5.01. ESSA Pharma shares last traded at $5.20, with a volume of 27,568 shares.
ESSA Pharma Price Performance
The firm has a 50-day moving average price of $5.88 and a 200 day moving average price of $5.70. The company has a market cap of $62.12 million, a price-to-earnings ratio of -2.26 and a beta of 1.83.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.10. On average, equities analysts anticipate that ESSA Pharma Inc. will post -0.71 EPS for the current fiscal year.
Hedge Funds Weigh In On ESSA Pharma
A hedge fund recently raised its stake in ESSA Pharma stock. Janus Henderson Group PLC raised its position in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 7.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,175,242 shares of the company's stock after purchasing an additional 85,760 shares during the quarter. Janus Henderson Group PLC owned 2.66% of ESSA Pharma worth $9,978,000 as of its most recent SEC filing. Institutional investors own 75.12% of the company's stock.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
